haloperidol has been researched along with Critical Illness in 60 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for sedation of non-intubated critically ill patients with hyperactive delirium in HDUs." | 9.69 | Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). ( Harada, H; Ikeda, K; Kamei, J; Kato, T; Kitajima, N; Kuriyama, A; Maeda, J; Matsuyama, A; Minami, T; Mizota, T; Ohtsuru, S; Sakai, Y; Sato, Y; Takatani, Y; Ueno, K; Watanabe, H; Yamaji, K; Yamashita, Y, 2023) |
| "Haloperidol does not reduce delirium in critically ill delirious adults." | 9.69 | Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. ( Boer, DP; Brouwers, AJBW; Devlin, JW; Gommers, DAMPJ; Hunfeld, NGM; Lens, JA; Osse, RJ; Ponssen, HH; Rietdijk, WJR; Schoonderbeek, JF; Simons, KS; Slooter, AJC; Smit, L; Trogrlic, Z; van den Boogaard, M; van der Jagt, M, 2023) |
| "A preplanned secondary analysis of long-term outcomes of the pRophylactic haloperidol usE for DeliriUm in iCu patients at high risk for dElirium (REDUCE) study was conducted." | 9.30 | Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study. ( Beishuizen, A; Pickkers, P; Rood, PJT; Simons, KS; Slooter, AJC; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PHJ; van der Woude, MCE; Zegers, M, 2019) |
| "In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo." | 9.27 | Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. ( Bernard, GR; Boehm, LM; Bowton, DL; Brummel, NE; Carson, SS; Chandrasekhar, R; Dittus, RS; Douglas, IS; Ely, EW; Exline, MC; Feinstein, DJ; Girard, TD; Gong, MN; Hite, RD; Hough, CL; Hughes, CG; Hyzy, RC; Jackson, JC; Khan, B; Malhotra, A; Masica, AL; Owens, RL; Pandharipande, PP; Patel, MB; Pisani, MA; Pun, BT; Rock, P; Schmidt, GA; Schweickert, WD; Stollings, JL; Strength, C; Thompson, JL, 2018) |
| "Results of studies on use of prophylactic haloperidol in critically ill adults are inconclusive, especially in patients at high risk of delirium." | 9.27 | Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. ( Beishuizen, A; Besselink, A; Brüggemann, RJM; de Koning, J; Dennesen, PJW; Donker, DW; Fuchs, M; Hannink, G; Hofstra, LS; Houterman, S; Karakus, A; Koeman, M; Pickkers, P; Pretorius, D; Schoonhoven, L; Simons, KS; Slooter, AJC; Spronk, PE; van den Bergh, W; van den Boogaard, M; van der Hoeven, JG; Van der Voort, PHJ; van Duijnhoven, M; Vermeijden, JW, 2018) |
| "Patients were randomly assigned to receive IV haloperidol 1 mg or placebo every 6 hours until delirium occurred (Intensive Care Delirium Screening Checklist ≥ 4 with psychiatric confirmation), 10 days of therapy had elapsed, or ICU discharge." | 9.22 | Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. ( Al-Qadheeb, NS; Devlin, JW; Pacheco, MN; Roberts, RJ; Ruthazer, RR; Schumaker, G; Skrobik, Y, 2016) |
| "This study was a before/after evaluation of a delirium prevention project using prophylactic treatment with haloperidol." | 9.17 | Haloperidol prophylaxis in critically ill patients with a high risk for delirium. ( Pickkers, P; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, JG, 2013) |
| "These results do not support the hypothesis that haloperidol modifies duration of delirium in critically ill patients." | 9.17 | Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. ( Alce, T; Ely, EW; Gates, S; Jackson, J; McAuley, DF; Page, VJ; Perkins, GD; Shintani, A; Zhao, XB, 2013) |
| "Rivastigmine did not decrease duration of delirium and might have increased mortality so we do not recommend use of rivastigmine to treat delirium in critically ill patients." | 9.14 | Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. ( Honing, ML; Karakus, A; Kesecioglu, J; Kuiper, MA; Roes, KC; Slooter, AJ; Spronk, PE; van der Jagt, M; van der Mast, RC; van Eijk, MM; van Gool, WA, 2010) |
| "The evidence for the use of haloperidol to treat critically ill patients with delirium is sparse, of low quality and inconclusive." | 9.05 | Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis. ( Andersen-Ranberg, NC; Barbateskovic, M; Collet, MO; Jakobsen, JC; Krauss, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2020) |
| "Our study is a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing haloperidol versus placebo for treatment and/or prophylaxis of ICU-related delirium." | 9.01 | Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials. ( Aburahma, A; Bachuwa, G; Banifadel, M; Barbarawi, M; Chahine, A; Haykal, T; Kheiri, B; Rashdan, L; Seedahmed, E; Zayed, Y, 2019) |
| "Haloperidol prophylaxis for preventing delirium." | 8.95 | Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review. ( Apóstolo, J; Cardoso, D; Cunha, M; Neves, H; Rodrigues, M; Santos, E, 2017) |
| "Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) patients, but it is unclear whether these agents may shorten the duration of delirium." | 8.02 | Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study. ( Dijkstra-Kersten, SMA; Slooter, AJC; Smit, L; van der Jagt, M; Zaal, IJ, 2021) |
| "Patients received preventive haloperidol or placebo for up to 28 days until delirium occurrence, death, or ICU discharge." | 8.02 | Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults. ( Briesacher, BA; Devlin, JW; Duprey, MS; Griffith, JL; Pickkers, P; Saczynski, JS; van den Boogaard, M; van der Hoeven, JG, 2021) |
| "To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults." | 7.96 | Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. ( Devlin, JW; Hunfeld, NGM; Koch, BCP; Nieboer, D; Osse, RJ; Trogrlić, Z; van der Jagt, M; van Schaik, RHN, 2020) |
| "From July 2014 until June 2015, when a potential delirium was identified by regular delirium scores and confirmed by a child psychiatrist, haloperidol was prescribed according to the Dutch Pediatric Formulary." | 7.88 | Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety. ( de Wildt, SN; Ista, E; Jessurun, N; Slooff, VD; Tibboel, D; van Beusekom, BS; van den Dungen, DK, 2018) |
| "Delirium is the most common mental disturbance in critically-ill patients and results in significant morbidity and mortality." | 6.48 | Haloperidol dosing strategies in the treatment of delirium in the critically ill. ( Ensom, MH; Loh, GW; Mabasa, VH; Wang, EH, 2012) |
| "Haloperidol does not reduce delirium in critically ill delirious adults." | 5.69 | Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. ( Boer, DP; Brouwers, AJBW; Devlin, JW; Gommers, DAMPJ; Hunfeld, NGM; Lens, JA; Osse, RJ; Ponssen, HH; Rietdijk, WJR; Schoonderbeek, JF; Simons, KS; Slooter, AJC; Smit, L; Trogrlic, Z; van den Boogaard, M; van der Jagt, M, 2023) |
| "This is the first randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for sedation of non-intubated critically ill patients with hyperactive delirium in HDUs." | 5.69 | Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). ( Harada, H; Ikeda, K; Kamei, J; Kato, T; Kitajima, N; Kuriyama, A; Maeda, J; Matsuyama, A; Minami, T; Mizota, T; Ohtsuru, S; Sakai, Y; Sato, Y; Takatani, Y; Ueno, K; Watanabe, H; Yamaji, K; Yamashita, Y, 2023) |
| "A preplanned secondary analysis of long-term outcomes of the pRophylactic haloperidol usE for DeliriUm in iCu patients at high risk for dElirium (REDUCE) study was conducted." | 5.30 | Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study. ( Beishuizen, A; Pickkers, P; Rood, PJT; Simons, KS; Slooter, AJC; Spronk, PE; van den Boogaard, M; van der Hoeven, JG; van der Voort, PHJ; van der Woude, MCE; Zegers, M, 2019) |
| "Results of studies on use of prophylactic haloperidol in critically ill adults are inconclusive, especially in patients at high risk of delirium." | 5.27 | Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial. ( Beishuizen, A; Besselink, A; Brüggemann, RJM; de Koning, J; Dennesen, PJW; Donker, DW; Fuchs, M; Hannink, G; Hofstra, LS; Houterman, S; Karakus, A; Koeman, M; Pickkers, P; Pretorius, D; Schoonhoven, L; Simons, KS; Slooter, AJC; Spronk, PE; van den Bergh, W; van den Boogaard, M; van der Hoeven, JG; Van der Voort, PHJ; van Duijnhoven, M; Vermeijden, JW, 2018) |
| "In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo." | 5.27 | Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. ( Bernard, GR; Boehm, LM; Bowton, DL; Brummel, NE; Carson, SS; Chandrasekhar, R; Dittus, RS; Douglas, IS; Ely, EW; Exline, MC; Feinstein, DJ; Girard, TD; Gong, MN; Hite, RD; Hough, CL; Hughes, CG; Hyzy, RC; Jackson, JC; Khan, B; Malhotra, A; Masica, AL; Owens, RL; Pandharipande, PP; Patel, MB; Pisani, MA; Pun, BT; Rock, P; Schmidt, GA; Schweickert, WD; Stollings, JL; Strength, C; Thompson, JL, 2018) |
| "Patients were randomly assigned to receive IV haloperidol 1 mg or placebo every 6 hours until delirium occurred (Intensive Care Delirium Screening Checklist ≥ 4 with psychiatric confirmation), 10 days of therapy had elapsed, or ICU discharge." | 5.22 | Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. ( Al-Qadheeb, NS; Devlin, JW; Pacheco, MN; Roberts, RJ; Ruthazer, RR; Schumaker, G; Skrobik, Y, 2016) |
| "These results do not support the hypothesis that haloperidol modifies duration of delirium in critically ill patients." | 5.17 | Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. ( Alce, T; Ely, EW; Gates, S; Jackson, J; McAuley, DF; Page, VJ; Perkins, GD; Shintani, A; Zhao, XB, 2013) |
| "This study was a before/after evaluation of a delirium prevention project using prophylactic treatment with haloperidol." | 5.17 | Haloperidol prophylaxis in critically ill patients with a high risk for delirium. ( Pickkers, P; Schoonhoven, L; van Achterberg, T; van den Boogaard, M; van der Hoeven, JG, 2013) |
| "Rivastigmine did not decrease duration of delirium and might have increased mortality so we do not recommend use of rivastigmine to treat delirium in critically ill patients." | 5.14 | Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. ( Honing, ML; Karakus, A; Kesecioglu, J; Kuiper, MA; Roes, KC; Slooter, AJ; Spronk, PE; van der Jagt, M; van der Mast, RC; van Eijk, MM; van Gool, WA, 2010) |
| "The evidence for the use of haloperidol to treat critically ill patients with delirium is sparse, of low quality and inconclusive." | 5.05 | Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis. ( Andersen-Ranberg, NC; Barbateskovic, M; Collet, MO; Jakobsen, JC; Krauss, SR; Mathiesen, O; Perner, A; Wetterslev, J, 2020) |
| "Our study is a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing haloperidol versus placebo for treatment and/or prophylaxis of ICU-related delirium." | 5.01 | Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials. ( Aburahma, A; Bachuwa, G; Banifadel, M; Barbarawi, M; Chahine, A; Haykal, T; Kheiri, B; Rashdan, L; Seedahmed, E; Zayed, Y, 2019) |
| "Haloperidol prophylaxis for preventing delirium." | 4.95 | Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review. ( Apóstolo, J; Cardoso, D; Cunha, M; Neves, H; Rodrigues, M; Santos, E, 2017) |
| "The use of antipsychotics for surgical ICU patients and dexmedetomidine for mechanically ventilated patients as a preventive strategy may reduce the prevalence of delirium in the ICU." | 4.91 | Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review. ( Bozza, FA; do Brasil, PE; Ely, EW; Salluh, JI; Serafim, RB; Soares, M; Tura, BR, 2015) |
| "Patients received preventive haloperidol or placebo for up to 28 days until delirium occurrence, death, or ICU discharge." | 4.02 | Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults. ( Briesacher, BA; Devlin, JW; Duprey, MS; Griffith, JL; Pickkers, P; Saczynski, JS; van den Boogaard, M; van der Hoeven, JG, 2021) |
| "Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) patients, but it is unclear whether these agents may shorten the duration of delirium." | 4.02 | Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study. ( Dijkstra-Kersten, SMA; Slooter, AJC; Smit, L; van der Jagt, M; Zaal, IJ, 2021) |
| "To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults." | 3.96 | Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. ( Devlin, JW; Hunfeld, NGM; Koch, BCP; Nieboer, D; Osse, RJ; Trogrlić, Z; van der Jagt, M; van Schaik, RHN, 2020) |
| "From July 2014 until June 2015, when a potential delirium was identified by regular delirium scores and confirmed by a child psychiatrist, haloperidol was prescribed according to the Dutch Pediatric Formulary." | 3.88 | Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety. ( de Wildt, SN; Ista, E; Jessurun, N; Slooff, VD; Tibboel, D; van Beusekom, BS; van den Dungen, DK, 2018) |
| "Completion of a survey containing 10 hypothetical ICU cases in which patients had agitated delirium for which a psychiatrist recommended intravenous haloperidol 5 mg every 6 hours." | 3.79 | Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation. ( Al-Qadheeb, NS; Devlin, JW; Estes, NA; Fongemie, JM; Roberts, RJ; Ruthazer, R; Temtanakitpaisan, Y, 2013) |
| "A 42-year-old woman who underwent single lung transplantation who received tacrolimus and a 58-year-old woman with pneumonia and multiple comorbidities who received haloperidol both experienced drug-induced prolongation of cardiac repolarization." | 3.72 | Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient. ( Akers, WS; Davis, GA; Flynn, JD; Green, AE; Strobel, G; Winstead, PS, 2004) |
| " Dosing recommendations however are often based on strategies used in patients with normal body habitus." | 2.66 | Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. ( Barletta, JF; Erstad, BL, 2020) |
| "Delirium is the most common mental disturbance in critically-ill patients and results in significant morbidity and mortality." | 2.48 | Haloperidol dosing strategies in the treatment of delirium in the critically ill. ( Ensom, MH; Loh, GW; Mabasa, VH; Wang, EH, 2012) |
| "Delirium is frequently encountered in the ICU and is associated with significant adverse outcomes." | 2.48 | ICU delirium: an update. ( Jones, SF; Pisani, MA, 2012) |
| "The prognosis of CCI patients with coma or delirium has not yet been thoroughly studied, but preliminary studies suggest this population is at high risk for detrimental outcomes associated with acute brain dysfunction." | 2.48 | Brain dysfunction in patients with chronic critical illness. ( Girard, TD, 2012) |
| " Neuroleptic drugs can produce severe side effects and need careful dosage and monitoring." | 2.44 | [Delusion in the critical patient]. ( Palencia-Herrejón, E; Romera, MA; Silva, JA, 2008) |
| "Propofol has many of the qualities of an ideal sedative agent." | 2.41 | Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. ( Angelini, G; Coursin, DB; Ketzler, JT, 2001) |
| "Haloperidol was associated with significantly lower hospital mortality." | 1.33 | Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. ( Angus, DC; Clermont, G; Fink, MP; Kersten, A; Kong, L; Milbrandt, EB; Weissfeld, LA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (10.00) | 18.2507 |
| 2000's | 8 (13.33) | 29.6817 |
| 2010's | 35 (58.33) | 24.3611 |
| 2020's | 11 (18.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshihiro, S | 1 |
| Taito, S | 1 |
| Minami, T | 1 |
| Watanabe, H | 1 |
| Kato, T | 1 |
| Ikeda, K | 1 |
| Ueno, K | 1 |
| Matsuyama, A | 1 |
| Maeda, J | 1 |
| Sakai, Y | 1 |
| Harada, H | 1 |
| Kuriyama, A | 1 |
| Yamaji, K | 1 |
| Kitajima, N | 1 |
| Kamei, J | 1 |
| Takatani, Y | 1 |
| Sato, Y | 1 |
| Yamashita, Y | 1 |
| Mizota, T | 1 |
| Ohtsuru, S | 1 |
| Smit, L | 3 |
| Slooter, AJC | 6 |
| Devlin, JW | 7 |
| Trogrlic, Z | 3 |
| Hunfeld, NGM | 3 |
| Osse, RJ | 3 |
| Ponssen, HH | 2 |
| Brouwers, AJBW | 1 |
| Schoonderbeek, JF | 1 |
| Simons, KS | 3 |
| van den Boogaard, M | 7 |
| Lens, JA | 1 |
| Boer, DP | 1 |
| Gommers, DAMPJ | 1 |
| Rietdijk, WJR | 2 |
| van der Jagt, M | 5 |
| Dietrich, M | 1 |
| Reuß, CJ | 1 |
| Beynon, C | 1 |
| Hecker, A | 1 |
| Jungk, C | 1 |
| Michalski, D | 1 |
| Nusshag, C | 1 |
| Schmidt, K | 1 |
| Weigand, MA | 1 |
| Bernhard, M | 1 |
| Brenner, T | 1 |
| Lewis, KA | 1 |
| Spence, J | 1 |
| Dionne, JC | 1 |
| Rochwerg, B | 1 |
| Barbateskovic, M | 1 |
| Krauss, SR | 1 |
| Collet, MO | 1 |
| Andersen-Ranberg, NC | 1 |
| Mathiesen, O | 1 |
| Jakobsen, JC | 1 |
| Perner, A | 1 |
| Wetterslev, J | 1 |
| Nieboer, D | 1 |
| Koch, BCP | 1 |
| van Schaik, RHN | 1 |
| Erstad, BL | 1 |
| Barletta, JF | 1 |
| Moskowitz, A | 1 |
| Andersen, LW | 1 |
| Holmberg, MJ | 1 |
| Grossestreuer, AV | 1 |
| Berg, KM | 1 |
| Granfeldt, A | 1 |
| Gommers, D | 1 |
| Dijkstra-Kersten, SMA | 1 |
| Zaal, IJ | 1 |
| Duprey, MS | 1 |
| van der Hoeven, JG | 4 |
| Pickkers, P | 6 |
| Briesacher, BA | 1 |
| Saczynski, JS | 1 |
| Griffith, JL | 1 |
| Santos, E | 2 |
| Cardoso, D | 2 |
| Neves, H | 2 |
| Cunha, M | 2 |
| Rodrigues, M | 2 |
| Apóstolo, J | 2 |
| Slooff, VD | 2 |
| van den Dungen, DK | 1 |
| van Beusekom, BS | 2 |
| Jessurun, N | 2 |
| Ista, E | 1 |
| Tibboel, D | 2 |
| de Wildt, SN | 2 |
| Brüggemann, RJM | 1 |
| Schoonhoven, L | 2 |
| Beishuizen, A | 2 |
| Vermeijden, JW | 1 |
| Pretorius, D | 1 |
| de Koning, J | 1 |
| Dennesen, PJW | 1 |
| Van der Voort, PHJ | 3 |
| Houterman, S | 1 |
| Besselink, A | 1 |
| Hofstra, LS | 1 |
| Spronk, PE | 3 |
| van den Bergh, W | 1 |
| Donker, DW | 1 |
| Fuchs, M | 1 |
| Karakus, A | 2 |
| Koeman, M | 1 |
| van Duijnhoven, M | 1 |
| Hannink, G | 1 |
| Fernandes, FM | 1 |
| Silva, EP | 1 |
| Martins, RR | 1 |
| Oliveira, AG | 1 |
| Strik, JJMH | 1 |
| Schieveld, JNM | 1 |
| Torbic, H | 1 |
| Duggal, A | 1 |
| van Schijndel, AW | 1 |
| Franssen, EJF | 1 |
| Rijkenberg, S | 1 |
| Bleck, TP | 1 |
| Girard, TD | 3 |
| Exline, MC | 1 |
| Carson, SS | 1 |
| Hough, CL | 1 |
| Rock, P | 1 |
| Gong, MN | 1 |
| Douglas, IS | 1 |
| Malhotra, A | 1 |
| Owens, RL | 1 |
| Feinstein, DJ | 1 |
| Khan, B | 1 |
| Pisani, MA | 2 |
| Hyzy, RC | 1 |
| Schmidt, GA | 1 |
| Schweickert, WD | 1 |
| Hite, RD | 1 |
| Bowton, DL | 1 |
| Masica, AL | 1 |
| Thompson, JL | 1 |
| Chandrasekhar, R | 1 |
| Pun, BT | 1 |
| Strength, C | 1 |
| Boehm, LM | 1 |
| Jackson, JC | 1 |
| Pandharipande, PP | 1 |
| Brummel, NE | 1 |
| Hughes, CG | 1 |
| Patel, MB | 1 |
| Stollings, JL | 1 |
| Bernard, GR | 1 |
| Dittus, RS | 1 |
| Ely, EW | 4 |
| Zayed, Y | 1 |
| Barbarawi, M | 1 |
| Kheiri, B | 1 |
| Banifadel, M | 1 |
| Haykal, T | 1 |
| Chahine, A | 1 |
| Rashdan, L | 1 |
| Aburahma, A | 1 |
| Bachuwa, G | 1 |
| Seedahmed, E | 1 |
| Khan, BA | 1 |
| Perkins, AJ | 1 |
| Campbell, NL | 1 |
| Gao, S | 1 |
| Farber, MO | 1 |
| Wang, S | 1 |
| Khan, SH | 1 |
| Zarzaur, BL | 1 |
| Boustani, MA | 1 |
| Tenser, RB | 1 |
| Oldham, MA | 1 |
| Neufeld, KJ | 1 |
| Lee, HB | 1 |
| Ishiki, H | 1 |
| Satomi, E | 1 |
| Shimizu, K | 1 |
| Rood, PJT | 1 |
| Zegers, M | 1 |
| van der Woude, MCE | 1 |
| Fongemie, JM | 1 |
| Al-Qadheeb, NS | 2 |
| Estes, NA | 1 |
| Roberts, RJ | 3 |
| Temtanakitpaisan, Y | 1 |
| Ruthazer, R | 2 |
| Jones, C | 1 |
| Page, VJ | 1 |
| Gates, S | 1 |
| Zhao, XB | 1 |
| Alce, T | 1 |
| Shintani, A | 1 |
| Jackson, J | 1 |
| Perkins, GD | 1 |
| McAuley, DF | 1 |
| Spaans, E | 1 |
| van Puijenbroek, E | 1 |
| de Hoog, M | 1 |
| Serafim, RB | 1 |
| Bozza, FA | 1 |
| Soares, M | 1 |
| do Brasil, PE | 1 |
| Tura, BR | 1 |
| Salluh, JI | 1 |
| Skrobik, Y | 2 |
| Schumaker, G | 1 |
| Pacheco, MN | 1 |
| Ruthazer, RR | 1 |
| Wang, LJ | 1 |
| Lee, SY | 1 |
| Yuan, SS | 1 |
| Yang, KC | 1 |
| Yang, CJ | 1 |
| Lee, TL | 1 |
| Shyu, YC | 1 |
| Corona, A | 2 |
| Colombo, R | 2 |
| Catena, E | 1 |
| van Eijk, MM | 1 |
| Roes, KC | 1 |
| Honing, ML | 1 |
| Kuiper, MA | 1 |
| van Gool, WA | 1 |
| van der Mast, RC | 1 |
| Kesecioglu, J | 1 |
| Slooter, AJ | 1 |
| Riker, RR | 2 |
| Hinderleider, E | 1 |
| Fong, JJ | 1 |
| Hill, NS | 1 |
| Garpestad, E | 1 |
| Wang, EH | 1 |
| Mabasa, VH | 1 |
| Loh, GW | 1 |
| Ensom, MH | 1 |
| Jones, SF | 1 |
| DeMuro, JP | 1 |
| Botros, DG | 1 |
| Wirkowski, E | 1 |
| Hanna, AF | 1 |
| Praga, F | 1 |
| Minari, C | 1 |
| Giannotti, C | 1 |
| Castelli, A | 1 |
| Raimondi, F | 1 |
| van Achterberg, T | 1 |
| Akers, WS | 1 |
| Flynn, JD | 1 |
| Davis, GA | 1 |
| Green, AE | 1 |
| Winstead, PS | 1 |
| Strobel, G | 1 |
| de Rooij, S | 1 |
| de Jonge, E | 1 |
| Milbrandt, EB | 1 |
| Kersten, A | 1 |
| Kong, L | 1 |
| Weissfeld, LA | 1 |
| Clermont, G | 1 |
| Fink, MP | 1 |
| Angus, DC | 1 |
| Schweickert, W | 1 |
| Hall, JB | 1 |
| Schieveld, JN | 1 |
| Leroy, PL | 1 |
| Leentjens, AF | 1 |
| Palencia-Herrejón, E | 1 |
| Romera, MA | 1 |
| Silva, JA | 1 |
| Crippen, D | 1 |
| Ermakov, S | 1 |
| Stern, TA | 1 |
| Fraser, GL | 1 |
| Cox, PM | 1 |
| Sharma, ND | 2 |
| Rosman, HS | 1 |
| Padhi, ID | 2 |
| Tisdale, JE | 2 |
| Hurford, WE | 1 |
| Angelini, G | 1 |
| Ketzler, JT | 1 |
| Coursin, DB | 1 |
| Rasty, S | 1 |
| Rosman, H | 1 |
| Ziehm, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Haloperidol to Decrease the Burden of Delirium in Adult Critically Ill Patients (EuRIDICE): a Prospective Randomised Multi-center Double-blind Placebo-controlled Clinical Trial[NCT03628391] | Phase 3 | 142 participants (Actual) | Interventional | 2018-02-22 | Terminated (stopped due to The study was stopped because of futility of being able to reach a one-day difference between treatment groups in the primary outcome of DCFD in the intended sample size.) | ||
| Virtual Reality Stimulation to Relax and Reduce the Incidence of Delirium[NCT04498585] | 920 participants (Anticipated) | Interventional | 2021-04-14 | Suspended (stopped due to Decreased resources due to COVID-19) | |||
| Prophylactic Haloperidol Use for Delirium in ICU Patients; a Randomized Placebo-controlled Double-blind Multicentre Trial[NCT01785290] | Phase 4 | 1,800 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Observational Study to Evaluate the Effects on the Qt Interval of COVID-19 Coronavirus Infection in Critically Ill Patients[NCT04422535] | 80 participants (Anticipated) | Observational | 2020-05-29 | Recruiting | |||
| Effect of Flumazenil on Hypoactive Delirium in the ICU: A Double-Blind, Placebo-Controlled Pilot Study[NCT02899156] | Phase 4 | 22 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to A planned interim analysis led to the trial being stopped early based on the observed size effect and power analysis.) | ||
| MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction[NCT01211522] | Phase 3 | 566 participants (Actual) | Interventional | 2011-12-14 | Completed | ||
| Pharmacological Management of Delirium[NCT00842608] | 551 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Structured Cognitive Therapy to Improve Neurocognitive Dysfunction in Older Intensive Care Unit Sepsis Survivors[NCT04081090] | 1 participants (Actual) | Interventional | 2019-01-15 | Terminated (stopped due to Delay due to COVID. Lost funding.) | |||
| Subsyndromal Delirium in Intensive Care Unit, a Multicenter Study[NCT03813459] | 400 participants (Actual) | Observational | 2018-08-01 | Completed | |||
| Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial[NCT00704301] | Phase 4 | 104 participants (Actual) | Interventional | 2008-11-30 | Terminated (stopped due to The study is prematurely terminated due to a safety issue) | ||
| Trazodone vs. Quetiapine for the Treatment of ICU Delirium: A Prospective Observational Pilot Study[NCT05307003] | 60 participants (Anticipated) | Observational | 2023-04-01 | Recruiting | |||
| Comparison of Trazodone vs Quetiapine vs Placebo for the Treatment of ICU Delirium: A Randomized Controlled Trial (The TraQ Study)[NCT05085808] | Phase 4 | 30 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| Southern Medical University Clinical Research Project Initiative：Efficacy and Safety of a Multicomponent Physical Therapy Program in Mechanically Ventilated Patient With Sepsis[NCT03406494] | 800 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | |||
| Evaluation Study of a Delirium Prevention Policy Using Prophylactic Haloperidol in Critically Ill Patients With a High Risk for Delirium[NCT01187667] | 650 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| A Randomized Prospective Pilot Study Of Haloperidol In Addition To Standard Sedation In Mechanically Ventilated Patients With Delirium[NCT00429676] | Phase 2 | 20 participants (Anticipated) | Interventional | 2005-12-31 | Completed | ||
| ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium[NCT00300391] | Phase 3 | 40 participants (Actual) | Interventional | 2006-03-31 | Terminated (stopped due to Insufficient recruitment to meet aims.) | ||
| Randomized Double-Blind Clinical Trial to Compare Haloperidol and Non-Pharmacologic Treatment Versus Non-Pharmacologic Treatment and Placebo, in Elderly Hospitalized Patients With Hypoactive Delirium[NCT02345902] | Phase 3 | 60 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
average duration of time patient was randomized to each infusion up to 72 hours (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | hours (Mean) |
|---|---|
| Flumazenil Group | 54.8 |
| Placebo Group | 58.2 |
average maximum rate (ml/hr) during the 72 hours after study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | milliliters per hour (Mean) |
|---|---|
| Flumazenil Group | 5 |
| Placebo Group | 5.2 |
length of time that the patient was admitted to an intensive care unit service during the hospital stay (NCT02899156)
Timeframe: duration of admission to the intensive care unit
| Intervention | days (Mean) |
|---|---|
| Flumazenil Group | 7.8 |
| Placebo Group | 7 |
Defined by the number of days in the 14-day period after randomization that the patient was alive and not delirious (i.e. CAM-ICU negative). Zero delirium-free days will be observed for patients that die within the 14-day period. (NCT02899156)
Timeframe: up to 14 days after randomization
| Intervention | days (Median) |
|---|---|
| Flumazenil Group | 12.7 |
| Placebo Group | 9.2 |
number of days within the first 28 days after enrollment that the patient was free from needing mechanical ventilation (NCT02899156)
Timeframe: up to 28 days after randomization
| Intervention | days (Mean) |
|---|---|
| Flumazenil Group | 23.6 |
| Placebo Group | 24.9 |
defined by the proportion of patients who were delirium free at 14 days after randomization (NCT02899156)
Timeframe: up to 14 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Flumazenil Group | 9 |
| Placebo Group | 7 |
number of times that a RASS score of + 2 to +4 occurred that did not resolve with decreasing study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Flumazenil Group | 0 |
| Placebo Group | 0 |
Duration of delirium during the intervention period (NCT01211522)
Timeframe: 14 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 4 |
| Ziprasidone | 4 |
| Placebo | 4 |
Defined as the number of days during the 14-day intervention period (beginning on the day of randomization) that the patient was alive and experienced neither delirium nor coma. (NCT01211522)
Timeframe: 14 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 8 |
| Ziprasidone | 8 |
| Placebo | 7 |
(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol | 1 |
| Ziprasidone | 1 |
| Placebo | 1 |
(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol | 0 |
| Ziprasidone | 0 |
| Placebo | 0 |
(NCT01211522)
Timeframe: 14 days plus 4-day post-study drug period (if longer than 14 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol | 2 |
| Ziprasidone | 0 |
| Placebo | 0 |
"Days from randomization to final, successful ICU discharge, where successful indicates that discharge was followed by at least 48 hours alive. ICU discharge is represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU." (NCT01211522)
Timeframe: 90 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 5 |
| Ziprasidone | 6 |
| Placebo | 5 |
"Days from randomization to successful hospital discharge, where successful indicates that discharge was followed by at least 48 hours alive." (NCT01211522)
Timeframe: 90 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 13 |
| Ziprasidone | 12 |
| Placebo | 13 |
Days from first ICU discharge to next ICU readmission. (NCT01211522)
Timeframe: 90 days after first ICU discharge
| Intervention | days (Median) |
|---|---|
| Haloperidol | 5 |
| Ziprasidone | 5 |
| Placebo | 4 |
"Days from randomization to successful liberation from mechanical ventilation, where successful indicates that liberation was followed by at least 48 hours alive and without reinitiation of invasive or noninvasive ventilation." (NCT01211522)
Timeframe: 30 days
| Intervention | days (Median) |
|---|---|
| Haloperidol | 2 |
| Ziprasidone | 3 |
| Placebo | 3 |
Deaths within the specified timeframe (NCT01211522)
Timeframe: 30-day and 90-day
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 30-day mortality | 90-day mortality | |
| Haloperidol | 50 | 73 |
| Placebo | 50 | 63 |
| Ziprasidone | 53 | 65 |
(NCT00842608)
Timeframe: Admission through day 8 of stay
| Intervention | days (Median) |
|---|---|
| Haloperidol Eligible Intervention | 4 |
| Haloperidol Eligible Usual Care | 5 |
| Haldol-Ineligible Arm | 4 |
| Haldol Ineligible Usual Care | 5 |
(NCT00842608)
Timeframe: Participants were followed for the duration of hospital stay, an average of 11 days
| Intervention | days (Mean) |
|---|---|
| Haloperidol Eligible Intervention | 20.2 |
| Haloperidol Eligible Usual Care | 18.6 |
| Haldol-Ineligible Arm | 18.8 |
| Haldol Ineligible Usual Care | 14.9 |
(NCT00842608)
Timeframe: ICU, in-hospital, 30-days post hospitalization
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Eligible Intervention | 20 |
| Haloperidol Eligible Usual Care | 32 |
| Haldol-Ineligible Arm | 11 |
| Haldol Ineligible Usual Care | 8 |
(NCT00300391)
Timeframe: Daily
| Intervention | Participants (Count of Participants) |
|---|---|
| Delirium | 4 |
| Persistent Coma | 2 |
| No Delirium | 1 |
(NCT00300391)
Timeframe: 90 Days from enrollment in study
| Intervention | Participants (Count of Participants) |
|---|---|
| Delirium | 4 |
| Persistent Coma | 2 |
| No Delirium | 1 |
(NCT00300391)
Timeframe: daily
| Intervention | day (Median) |
|---|---|
| Delirium | 4.5 |
| Persistent Coma | 6 |
| No Delirium | 4 |
(NCT00300391)
Timeframe: Daily
| Intervention | day (Median) |
|---|---|
| Delirium | 9 |
| Persistent Coma | 6 |
| No Delirium | 7 |
12 reviews available for haloperidol and Critical Illness
| Article | Year |
|---|---|
Haloperidol for the treatment of delirium in critically ill patients: A systematic review with meta-analysis and Trial Sequential Analysis.
Topics: Bias; Cause of Death; Cognition; Critical Illness; Delirium; Electrocardiography; Haloperidol; Human | 2020 |
Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.
Topics: Analgesia; Analgesics, Non-Narcotic; Analgesics, Opioid; Benzodiazepines; Critical Illness; Deep Sed | 2020 |
Identification, collection, and reporting of harms among non-industry-sponsored randomized clinical trials of pharmacologic interventions in the critically ill population: a systematic review.
Topics: Adrenal Cortex Hormones; Antipsychotic Agents; Critical Illness; Dexmedetomidine; Drug-Related Side | 2020 |
Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Critical | 2017 |
Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units; | 2019 |
Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review.
Topics: Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Dexmedetomidine; Haloperidol; Human | 2015 |
Haloperidol dosing strategies in the treatment of delirium in the critically ill.
Topics: Antipsychotic Agents; Critical Illness; Delirium; Dose-Response Relationship, Drug; Drug Administrat | 2012 |
ICU delirium: an update.
Topics: Anesthesia, General; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Female; Halope | 2012 |
Brain dysfunction in patients with chronic critical illness.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chronic Disease; Coma; Comorbid | 2012 |
[Delusion in the critical patient].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Illness; Delusions; Diagnostic and Statistical Manua | 2008 |
Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit.
Topics: Critical Illness; Dexmedetomidine; Etomidate; Haloperidol; Humans; Hypnotics and Sedatives; Intensiv | 2001 |
Intravenous haloperidol for tranquilization in critical care patients: a review and critique.
Topics: Aged; Basal Ganglia Diseases; Critical Illness; Death, Sudden; Female; Haloperidol; Humans; Infusion | 1991 |
13 trials available for haloperidol and Critical Illness
| Article | Year |
|---|---|
Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial).
Topics: Critical Illness; Delirium; Dexmedetomidine; Drugs, Investigational; Haloperidol; Humans; Hypnotics | 2023 |
Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial.
Topics: Adult; Aged; Antipsychotic Agents; Coma; Critical Illness; Delirium; Female; Haloperidol; Humans; In | 2023 |
Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre double-blind placebo-controlled clinical trial in the Netherlands.
Topics: Adult; Critical Illness; Delirium; Double-Blind Method; Haloperidol; Humans; Intensive Care Units; M | 2020 |
Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.
Topics: Adult; Aged; Antipsychotic Agents; Critical Illness; Delirium; Dose-Response Relationship, Drug; Dou | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; F | 2018 |
Pharmacological Management of Delirium in the Intensive Care Unit: A Randomized Pragmatic Clinical Trial.
Topics: Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Critical Illness; Delirium; Dose-Res | 2019 |
Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study.
Topics: Aged; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Double-Blind Method; Female; | 2019 |
Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Coma; Critical Care; Critical Illness; Delirium; Dopamine Antagonists; Double-Blind Method; Fe | 2013 |
Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study.
Topics: Administration, Intravenous; Adult; Aged; Antipsychotic Agents; Coma; Critical Illness; Delirium; Do | 2016 |
Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cholinesterase Inhibitors; Critical Care; Critical Il | 2010 |
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha | 2011 |
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha | 2011 |
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha | 2011 |
Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Dibenzothiazepines; Double-Blind Method; Ha | 2011 |
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.
Topics: Acoustic Stimulation; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Critical Care; | 2012 |
Haloperidol prophylaxis in critically ill patients with a high risk for delirium.
Topics: Aged; Antipsychotic Agents; Critical Illness; Delirium; Double-Blind Method; Female; Haloperidol; Hu | 2013 |
35 other studies available for haloperidol and Critical Illness
| Article | Year |
|---|---|
Concerns With Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults.
Topics: Adult; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units | 2022 |
[Additive therapies : Intensive care studies from 2018-2019].
Topics: Critical Care; Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2020 |
Critical Care Prophylaxis. Sometimes Less Is More.
Topics: Adult; Critical Care; Critical Illness; Delirium; Haloperidol; Humans | 2019 |
Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium.
Topics: Adult; Aged; Antipsychotic Agents; Critical Illness; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A | 2020 |
Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study.
Topics: Clonidine; Cohort Studies; Critical Illness; Delirium; Haloperidol; Humans; Intensive Care Units; Pr | 2021 |
Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults.
Topics: Adult; Aged; Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Female; Haloperidol; H | 2021 |
Monitoring Haloperidol Plasma Concentration and Associated Adverse Events in Critically Ill Children With Delirium: First Results of a Clinical Protocol Aimed to Monitor Efficacy and Safety.
Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Clinical Protocols; Critical Illness; Del | 2018 |
QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications.
Topics: Adult; Aged; Amiodarone; Clopidogrel; Critical Illness; Cross-Sectional Studies; Electrocardiography | 2018 |
Prophylactic Haloperidol for Critically Ill Adults.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans | 2018 |
Prophylactic Haloperidol for Critically Ill Adults.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans | 2018 |
Prophylactic Haloperidol for Critically Ill Adults-Reply.
Topics: Adult; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans | 2018 |
Haloperidol serum concentrations in critically ill patients included in the REDUCE study.
Topics: Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans | 2018 |
Dopamine Antagonists in ICU Delirium.
Topics: Critical Illness; Delirium; Dopamine Antagonists; Haloperidol; Humans; Intensive Care Units; Piperaz | 2018 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. Reply.
Topics: Critical Illness; Delirium; Haloperidol; Humans; Piperazines; Thiazoles | 2019 |
Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation.
Topics: Antipsychotic Agents; Critical Illness; Decision Making; Delirium; Haloperidol; Health Care Surveys; | 2013 |
What's new on the post-ICU burden for patients and relatives?
Topics: Antipsychotic Agents; Cognition Disorders; Critical Illness; Delirium; Family; Haloperidol; Humans; | 2013 |
Adverse events of haloperidol for the treatment of delirium in critically ill children.
Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Critical Illness; Delirium; Female; Halop | 2014 |
Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk for delirium: a systematic review of quantitative evidence protocol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Critical Illness; Delirium; Haloperidol; Humans; Inte | 2015 |
Risk of Mortality Among Patients Treated With Antipsychotic Medications: A Nationwide Population-Based Study in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chlorpromazine; Critical Illness; | 2016 |
Early Identification of Subsyndromal Delirium in the Critically Ill: Don't Let the Delirium Rise!
Topics: Antipsychotic Agents; Critical Illness; Delirium; Female; Haloperidol; Humans; Male | 2016 |
Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: a retrospective case series.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Withdrawal Delirium; Antipsychotic Agents; Benzodiazepines; | 2012 |
Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient.
Topics: Administration, Oral; Adult; Critical Illness; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Reply to the comment by Skrobik et al.
Topics: Antipsychotic Agents; Benzodiazepines; Critical Illness; Delirium; Haloperidol; Humans; Olanzapine; | 2004 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne | 2005 |
Agitation in the critically ill patient: a marker of health or a plea for treatment?
Topics: Antipsychotic Agents; Conscious Sedation; Critical Care; Critical Illness; Delirium; Haloperidol; Ho | 2005 |
[Delirium in critically ill children in a paediatric intensive care unit].
Topics: Antipsychotic Agents; Child, Preschool; Critical Illness; Delirium; Diagnosis, Differential; Female; | 2006 |
Continuous infusions of haloperidol in critically ill patients.
Topics: Critical Illness; Haloperidol; Humans; Infusions, Intravenous; Psychomotor Agitation | 1995 |
Continuous infusion of haloperidol in agitated, critically ill patients.
Topics: Critical Illness; Haloperidol; Humans; Infusions, Intravenous; Psychomotor Agitation; Torsades de Po | 1994 |
Continuous infusion of haloperidol controls agitation in critically ill patients.
Topics: Adolescent; Adult; Clinical Protocols; Conscious Sedation; Critical Illness; Female; Haloperidol; Hu | 1994 |
Torsades de Pointes associated with intravenous haloperidol in critically ill patients.
Topics: Adult; Aged; Case-Control Studies; Critical Illness; Dopamine Antagonists; Electrocardiography; Fema | 1998 |
Sedation in the intensive care unit.
Topics: Analgesics, Opioid; Anesthetics, General; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Benzod | 1999 |
The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
Topics: Aged; Antipsychotic Agents; Critical Illness; Diagnosis, Computer-Assisted; Electrocardiography; Fem | 2001 |